These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27510617)

  • 21. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
    Parrish RH; Pazdur DE; O'donnell PJ
    Pharmacotherapy; 2006 Nov; 26(11):1650-3. PubMed ID: 17064211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation.
    Nelson WW; Milentijevic D; Wang L; Baser O; Damaraju CV; Schein JR
    Blood Coagul Fibrinolysis; 2016 Dec; 27(8):899-906. PubMed ID: 26886362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
    Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
    J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment.
    Lane D; Lip GY
    Age Ageing; 2005 Jan; 34(1):1-3. PubMed ID: 15591476
    [No Abstract]   [Full Text] [Related]  

  • 25. Atrial fibrillation and stroke risk prevention in real-life clinical practice.
    Tay KH; Lip GY; Lane DA
    Thromb Haemost; 2009 Mar; 101(3):415-6. PubMed ID: 19277398
    [No Abstract]   [Full Text] [Related]  

  • 26. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden.
    Björholt I; Andersson S; Nilsson GH; Krakau I
    BMC Fam Pract; 2007 Feb; 8():6. PubMed ID: 17324260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral anticoagulation and stroke in atrial fibrillation.
    Epstein EF; Natarajan I
    N Engl J Med; 2003 Dec; 349(24):2360-1; author reply 2360-1. PubMed ID: 14674042
    [No Abstract]   [Full Text] [Related]  

  • 28. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation.
    Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
    Int J Clin Pharm; 2015 Feb; 37(1):53-9. PubMed ID: 25428444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting patients with atrial fibrillation and improving their anticoagulation management.
    Kamath S; Lip GY
    Clin Cardiol; 2001 May; 24(5):355-7. PubMed ID: 11346241
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral anticoagulation and stroke in atrial fibrillation.
    Boos CJ
    N Engl J Med; 2003 Dec; 349(24):2360-1; author reply 2360-1. PubMed ID: 14674043
    [No Abstract]   [Full Text] [Related]  

  • 31. Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR target (2.0 to 3.0) or a lower range?
    Lane DA; Lip GY
    Thromb Haemost; 2010 Feb; 103(2):254-6. PubMed ID: 20076858
    [No Abstract]   [Full Text] [Related]  

  • 32. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.
    Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):585-99. PubMed ID: 26725259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
    Palagummi P; Saltzman H; Ezekowitz M
    Am Heart J; 2005 Jan; 149(1 Suppl):S32-5. PubMed ID: 15644791
    [No Abstract]   [Full Text] [Related]  

  • 35. Urine Metabolites as a Predictor of Warfarin Response Based on INR in Atrial Fibrillation.
    Bawadikji AA; Teh CH; Kader MABSA; Sulaiman SAS; Ibrahim B
    Curr Drug Metab; 2022 Aug; 23(5):415-422. PubMed ID: 35422207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation.
    Cheung CM; Tsoi TH; Huang CY
    Cerebrovasc Dis; 2005; 20(2):114-9. PubMed ID: 16006759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation.
    Arık OZ; Ozkan B; Kutlu R; Karal H; Sahin DY; Kaypaklı O; Ozel D; Cayli M
    Platelets; 2014; 25(5):311-6. PubMed ID: 23971881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?
    Topcuoglu MA; Arsava EM
    Turk Kardiyol Dern Ars; 2021 Jun; 49(4):254-256. PubMed ID: 34106058
    [No Abstract]   [Full Text] [Related]  

  • 39. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation--the J-RHYTHM Registry study design.
    Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
    J Cardiol; 2011 Jan; 57(1):95-9. PubMed ID: 20934857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should the newer oral anticoagulants be withheld from patients with valvular AF?
    Dalen JE
    Chest; 2013 Aug; 144(2):369-370. PubMed ID: 23918100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.